Phase II trial of inotuzumab ozogamicin to treat MRD+ B-ALL

Phase II trial of inotuzumab ozogamicin to treat MRD+ B-ALL

Inotuzumab ozogamicin & venetoclax in the treatment of B-ALL: findings from a Phase I trialПодробнее

Inotuzumab ozogamicin & venetoclax in the treatment of B-ALL: findings from a Phase I trial

Inotuzumab ozogamicin for MRD-positive B-ALLПодробнее

Inotuzumab ozogamicin for MRD-positive B-ALL

Inotuzumab ozogamicin for treating pediatric R/R ALLПодробнее

Inotuzumab ozogamicin for treating pediatric R/R ALL

Phase II study shows blinatumomab achieves minimal residual disease response in ALLПодробнее

Phase II study shows blinatumomab achieves minimal residual disease response in ALL

A Phase II adaptive study of dasatinib and inotuzumab-based induction for newly diagnosed Ph+ ALLПодробнее

A Phase II adaptive study of dasatinib and inotuzumab-based induction for newly diagnosed Ph+ ALL

Update on the INO-VATE trial: inotuzumab vs chemotherapy for ALLПодробнее

Update on the INO-VATE trial: inotuzumab vs chemotherapy for ALL

Inotuzumab ozogamicin for the treatment of elderly acute lymphoblastic leukemiaПодробнее

Inotuzumab ozogamicin for the treatment of elderly acute lymphoblastic leukemia

Phase II study of inotuzumab ozogamicin in MRD+ B-ALLПодробнее

Phase II study of inotuzumab ozogamicin in MRD+ B-ALL

A phase II study of blinatumomab for the treatment of MRD-positive B-cell acute lymphoblastic le...Подробнее

A phase II study of blinatumomab for the treatment of MRD-positive B-cell acute lymphoblastic le...

Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukaemia: results of ...Подробнее

Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukaemia: results of ...

INO-VATE trial of inotuzumab ozogamicin: response, efficacy and safety resultsПодробнее

INO-VATE trial of inotuzumab ozogamicin: response, efficacy and safety results

Emerging novel approaches for ALL: inotuzumab ozogamicinПодробнее

Emerging novel approaches for ALL: inotuzumab ozogamicin

The addition of inotuzumab ozogamicin to hyper-CVAD + blinatumomab in patients with B-ALLПодробнее

The addition of inotuzumab ozogamicin to hyper-CVAD + blinatumomab in patients with B-ALL

Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in Philadelphia chromosone-n...Подробнее

Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in Philadelphia chromosone-n...

Is inotuzumab ozogamicin with low-dose chemotherapy effective in treating ALL in elderly patients?Подробнее

Is inotuzumab ozogamicin with low-dose chemotherapy effective in treating ALL in elderly patients?

Antibody Therapy in ALL: How and Why to Integrate Antibody-Based Treatment Into Patient ManagementПодробнее

Antibody Therapy in ALL: How and Why to Integrate Antibody-Based Treatment Into Patient Management

The evolving role of inotuzumab ozogamicin in the treatment of pediatric & older patients with ALLПодробнее

The evolving role of inotuzumab ozogamicin in the treatment of pediatric & older patients with ALL

Hyper-CVAD with blinatumomab and inotuzumab ozogamicin for patients with newly diagnosed Ph- B-ALLПодробнее

Hyper-CVAD with blinatumomab and inotuzumab ozogamicin for patients with newly diagnosed Ph- B-ALL

Choosing between inotuzumab ozogamicin and blinatumomab in patients with R/R ALLПодробнее

Choosing between inotuzumab ozogamicin and blinatumomab in patients with R/R ALL